Rayner announces full release of RayOne Galaxy spiral IOL
Posted on 15/01/2025
In September 2024, Rayner – a global manufacturer of products for cataract surgery based in the UK – unveiled the world’s first spiral IOL at the ESCRS congress in Barcelona. Today, following a large-scale multicentre data collection study, Rayner announces the full commercial release of RayOne Galaxy and RayOne Galaxy Toric, marking a wider global rollout of its next-generation full range of focus intraocular lenses.
RayOne Galaxy sets a new standard for what surgeons can offer their premium lens replacement patients. Developed with AI, its unique non-diffractive spiral optic delivers a smooth and continuous full range of vision with minimised dysphotopsia and 0% loss of transmitted light.*
Ten leading surgeons from ten countries conducted a pre-launch clinical evaluation, with over 180 eyes treated with RayOne Galaxy and RayOne Galaxy Toric – collecting postoperative clinical outcomes at 1 and 3 months. Interim outcomes show that RayOne Galaxy and RayOne Galaxy Toric provide:
- A full range of vision, without the wave-like defocus pattern associated with diffractive trifocal IOLs.
- Mean corrected and uncorrected visual acuities at all distances of 0.1 logMAR or better.*
- Binocular defocus curve VA of 0.2 logMAR or better across a ~4.0 D range.*
- Less halo and glare compared to published data on diffractive trifocal IOLs.
- In a pre-clinical study of 30 subjects with healthy eyes, RayOne Galaxy demonstrated a halo size closer to that of an enhanced monofocal IOL than a diffractive trifocal IOL.**
Dr Francesco Carones, who took part in the initial clinical evaluation, said “I have had the opportunity to implant RayOne Galaxy during Rayner’s pre-launch clinical phase, and it was immediately apparent that this IOL can provide a very long range of focus with minimal compromises on the quality of night vision. I think this IOL represents a significant step forward in the technologies available to provide patients with very reduced spectacle dependence following lens replacement for cataract or refractive purposes.”
Between October and December 2024, RayOne Galaxy and RayOne Galaxy Toric have been available in a limited release phase to selective surgeons, allowing Rayner to collect further valuable insights before the full commercial release.
Tim Clover, Rayner CEO, echoed “With over 6,000 lenses now in the market, we want to thank everyone who has placed their trust in our new lens technology. The response and enthusiasm from our customers around the world has been phenomenal and we look forward to seeing more patients achieving excellent results with the world’s first spiral IOL.”
The RayOne Galaxy spiral IOL platform is now available to all surgeons, subject to local regulatory approval. Speak to your Rayner representative today or visit www.rayner.com/Galaxy to discover more.
References:
*Rayner 2025. Data on file.
**Amon et al. ACMIT study. Presented at ESCRS 2024.
About Rayner:
Since the implantation of the first Rayner intraocular lens by Sir Harold Ridley 1949, Rayner has the goal to improve vision and restore sight worldwide. Today, Rayner’s mission remains to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients.
Headquartered in Worthing, United Kingdom, Rayner markets its medical devices, pharmaceuticals, and digital solutions worldwide in over 80 countries through a network of distributors and includes direct sales teams in the United Kingdom, Eire, USA, Canada, Brazil, India, Poland, Australia, Germany, Austria, Switzerland, France, Italy, Spain, and Portugal.
Not all Rayner products are approved for sale in every country. Please contact your local Rayner distributor for details of which products are available in your area.
©2025 Rayner Group, all rights reserved. ‘Rayner’, ‘RayOne’ and ‘Galaxy’ are proprietary marks of the Rayner Group. All other trademarks are property of their respective owners.
Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ | EC 2025-01 EN